Barclays’s ANACOR PHARMACEUTICALS INC COM ANAC Stock Holding History

Barclays’s Portfolio ANAC Stock Details ANAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-27,500	Closed	-$3.08M	–	6930
2015 Q4	$3.08M	Buy	+27,500	New	+$3.03M	﹤0.01%	1681
2015 Q2	–	Sell	-5,000	Closed	-$285K	–	7550
2015 Q1	$285K	Buy	+5,000	New	+$212K	﹤0.01%	4083

Other funds holding ANAC

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

CIM

CIM Investment Management Pittsburgh, Pennsylvania $375M AUM 32.03% 1-Year Est. Return

Barclays's ANAC Position: Q2 2016 in Review

Barclays sold out of ANACOR PHARMACEUTICALS INC COM (ANAC) in Q2 2016, closing a stake of 4,828 shares — an estimated $256K sold.

Barclays first reported a position in ANAC in Q2 2013 and held it in 12 quarters. The position peaked at $5.84M in Q4 2015. 2 funds tracked by Wall St. Rank hold ANAC as of Q2 2016.

Barclays reported no remaining ANACOR PHARMACEUTICALS INC COM position as of Q2 2016 after selling out during the quarter.
Barclays sold 4,828 ANACOR PHARMACEUTICALS INC COM shares in Q2 2016, an estimated $256K.
Barclays first reported a position in ANACOR PHARMACEUTICALS INC COM in Q2 2013 and held it in 12 quarters.
Barclays's ANACOR PHARMACEUTICALS INC COM position peaked at $5.84M in Q4 2015.
2 funds tracked by Wall St. Rank held ANACOR PHARMACEUTICALS INC COM as of Q2 2016.

Based on Barclays's 13F filing for Q2 2016, filed 12 Aug 2016.